Relief is coming: In what Bloomberg notes is Mylan's second move after an explosion of criticism over the price of its EpiPens, the company on Monday announced it will start selling a cheaper version. The drugmaker says it will make available in the next several weeks a generic EpiPen that is identical to the branded option but will have a list price of $300 for a two-pack; the current two-pack sells for $608, reports the AP. The list price for a pair of EpiPens has climbed repeatedly from around $94 in 2007. The generic will be available in both 0.15-milligram and 0.30-milligram strengths, like the current version on the market.
Last week, Mylan doubled the limit for eligibility for its patient assistance program, so a family of four making up to $97,200 would pay nothing out of pocket. It also said it will offer $300 copay cards, up from the current $100 per-prescription savings. A company representative said Monday that the $300 cards would be available only for the branded version, but patients could use its assistance program for both the branded and generic versions of the medicine. Mylan's announcement Monday comes a few days after the compounding pharmacy Imprimis Pharmaceuticals said it might be able to sell a version of the allergy treatment in a few months and would likely charge around $100 for two injectors. There is currently an EpiPen alternative, but there's a catch. (More EpiPen stories.)
,
uBlock 
,
and
Ghostery 
)
